



22 August 2016

Letter from the Chairman

To the Shareholders of Optiscan:

Update on cooperation with Carl Zeiss Meditec: Prototypes approved

Execution of our key responsibilities under the co-operation agreements with Carl Zeiss Meditec (Zeiss) continues to be a focus for Optiscan.

In May 2016, as part of our previously announced collaboration project, Optiscan provided Zeiss with two split-system prototypes. We are delighted to announce that we have now received endorsement of the prototypes from Zeiss.

Zeiss are the pre-eminent market force in the microsurgical visualisation market and their engagement with Optiscan is therefore a key endorsement of Optiscan's technology. Zeiss believes that CNEM (confocal neuro endomicroscopy) is a significant development enabling new applications in neurosurgery and related disciplines that will become important tools for diagnostic visualisation in the operating room.

In a previous announcement (25 July 2016), we indicated that the Rights Issue was being used, in part, for "Completion and Launch of the Carl Zeiss Collaboration project".

Now that we have received funds from the Rights Issue (announced Friday 19 August), we will use some of the funds received to make requested minor modifications to the prototypes and progress to completion and launch.

We anticipate meeting with Zeiss in Germany in the near future and will provide further updates on progress at that time.

Kind regards,

Alan Hoffman
Chairman

About Optiscan

Optiscan is an Australian company that has developed and patented miniaturised confocal microscopes, and is a global leader in the development and application of microscopic imaging and related technologies for medical markets.

Further information:

Alan Hoffman
Chairman
Mb: +61 408 968 013
Em: alanh@optiscan.com

Archie Fraser
CEO
Ph: +61 3 9538 3333
Em: archief@optiscan.com